Phosphoinositides as membrane organizers
Phosphoinositides are signalling lipids derived from phosphatidylinositol, a ubiquitous
phospholipid in the cytoplasmic leaflet of eukaryotic membranes. Initially discovered for their …
phospholipid in the cytoplasmic leaflet of eukaryotic membranes. Initially discovered for their …
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
Cancer is the second leading cause of human death globally. PI3K/Akt/mTOR signaling is
one of the most frequently dysregulated signaling pathways observed in cancer patients that …
one of the most frequently dysregulated signaling pathways observed in cancer patients that …
Metabolic reprogramming and cancer progression
BACKGROUND Metabolic reprogramming is a hallmark of malignancy first recognized a
century ago. In some cases, reprogrammed metabolic activities can be exploited to …
century ago. In some cases, reprogrammed metabolic activities can be exploited to …
Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
Background PIK3CA mutations occur in approximately 40% of patients with hormone
receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast …
receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast …
At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy
Numerous agents targeting various phosphatidylinositol 3-kinase (PI3K) pathway
components, including PI3K, AKT and mTOR, have been tested in oncology clinical trials …
components, including PI3K, AKT and mTOR, have been tested in oncology clinical trials …
Develo** dietary interventions as therapy for cancer
Cancer cells acquire distinct metabolic preferences based on their tissue of origin, genetic
alterations and degree of interaction with systemic hormones and metabolites. These …
alterations and degree of interaction with systemic hormones and metabolites. These …
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
Abstract Purpose The therascreen PIK3CA mutation assay and the alpha-specific PI3K
inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced …
inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced …
Metabolic pathways in obesity-related breast cancer
KA Brown - Nature Reviews Endocrinology, 2021 - nature.com
This Review focuses on the mechanistic evidence for a link between obesity, dysregulated
cellular metabolism and breast cancer. Strong evidence now links obesity with the …
cellular metabolism and breast cancer. Strong evidence now links obesity with the …
[HTML][HTML] Insulin signal transduction perturbations in insulin resistance
Type 2 diabetes mellitus is a widespread medical condition, characterized by high blood
glucose and inadequate insulin action, which leads to insulin resistance. Insulin resistance …
glucose and inadequate insulin action, which leads to insulin resistance. Insulin resistance …